Clinical Trial

A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 7, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label, dose-escalation trial, planning to enroll 3-9 patients with transfusion-dependent β-thalassemia, aimed at assessing the safety and tolerability of a single-dose of YOLT-204 in patients with transfusion-dependent β-thalassemia; to preliminarily evaluate the impact of a single -dose of YOLT-204 on the levels of fetal hemoglobin in the plasma
Trial Details
NCT Number NCT06678165
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions Transfusion Dependent Beta Thalassemia
Enrollment 3 participants
Start Date 2024-12-31
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-11-07